Matinas BioPharma (NYSEAMERICAN:MTNB) Posts Quarterly Earnings Results, Hits Estimates

Matinas BioPharma (NYSEAMERICAN:MTNB) released its quarterly earnings results on Wednesday. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.02), Zacks reports.

Matinas BioPharma Price Performance

Matinas BioPharma stock opened at $0.14 on Friday. The stock has a market cap of $35.09 million, a P/E ratio of -1.17 and a beta of 1.70. Matinas BioPharma has a 52 week low of $0.12 and a 52 week high of $0.89.

About Matinas BioPharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.